NervGen Pharma (NGEN) news

Recent news

Nervgen Pharma Corp: Leerink Partners initiates coverage with outperform rating; price target $10

Leerink Partners has initiated coverage of NervGen Pharma Corp. (NASDAQ: NGEN) with an "Outperform" rating and a price target of $10 per share , according to a recent report. The decision follows the company’s recent progress in advancing its lead therapeutic candidate, NVG-291, through clinical…

AInvest Wire · Jul 13, 2026

Nervgen Pharma files $250M mixed securities shelf

AInvest Wire · May 26, 2026

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by